WallStreetZenWallStreetZen

NASDAQ: VRCA
Verrica Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for VRCA

Based on 1 analyst offering 12 month price targets for Verrica Pharmaceuticals Inc

Min Forecast
$12.00+154.24%
Avg Forecast
$12.00+154.24%
Max Forecast
$12.00+154.24%

Should I buy or sell VRCA stock?

Based on 1 analyst offering ratings for Verrica Pharmaceuticals Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although VRCA's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates VRCA as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -6.47% per year. Learn More

Be the first to know when Wall Street analysts revise their VRCA stock forecasts and price targets.

VRCA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-05-26

1 of 1

Forecast return on equity

Is VRCA forecast to generate an efficient return?

Company
956.06%
Industry
19.26%
Market
167.68%
VRCA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is VRCA forecast to generate an efficient return on assets?

Company
114.33%
Industry
23.46%
VRCA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

VRCA earnings per share forecast

What is VRCA's earnings per share in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
-$2.14
Avg 2 year Forecast
-$1.44
Avg 3 year Forecast
-$0.64

VRCA revenue forecast

What is VRCA's revenue in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
$25.7M-15.26%
Avg 2 year Forecast
$40.6M+33.84%
Avg 3 year Forecast
$60.9M+100.9%
VRCA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

VRCA revenue growth forecast

How is VRCA forecast to perform vs Biotechnology companies and vs the US market?

Company
25.49%
Industry
31.66%
Market
13.96%
VRCA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
VRCA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

VRCA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
VRCA$4.72$12.00+154.24%Buy
PMVP$1.51$5.00+231.13%Buy
OSTX$1.77$13.33+653.28%Strong Buy
FBIO$2.45N/AN/A
NTRB$6.76N/AN/A
View Top Biotech Stocks

Verrica Pharmaceuticals Stock Forecast FAQ

Is Verrica Pharmaceuticals Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: VRCA) stock is to Buy VRCA stock.

Out of 1 analyst, 0 (0%) are recommending VRCA as a Strong Buy, 1 (100%) are recommending VRCA as a Buy, 0 (0%) are recommending VRCA as a Hold, 0 (0%) are recommending VRCA as a Sell, and 0 (0%) are recommending VRCA as a Strong Sell.

If you're new to stock investing, here's how to buy Verrica Pharmaceuticals stock.

What is VRCA's earnings growth forecast for 2026-2028?

(NASDAQ: VRCA) Verrica Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.22%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.68%.

Verrica Pharmaceuticals's earnings in 2026 is -$31,183,000.On average, 9 Wall Street analysts forecast VRCA's earnings for 2026 to be -$36,803,831, with the lowest VRCA earnings forecast at -$39,731,096, and the highest VRCA earnings forecast at -$35,209,640. On average, 9 Wall Street analysts forecast VRCA's earnings for 2027 to be -$24,794,142, with the lowest VRCA earnings forecast at -$31,818,547, and the highest VRCA earnings forecast at -$16,955,462.

In 2028, VRCA is forecast to generate -$11,039,088 in earnings, with the lowest earnings forecast at -$24,916,111 and the highest earnings forecast at $18,578,857.

What is VRCA's revenue growth forecast for 2026-2028?

(NASDAQ: VRCA) Verrica Pharmaceuticals's forecast annual revenue growth rate of 25.49% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.66%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.96%.

Verrica Pharmaceuticals's revenue in 2026 is $30,321,000.On average, 9 Wall Street analysts forecast VRCA's revenue for 2026 to be $441,374,549, with the lowest VRCA revenue forecast at $392,002,718, and the highest VRCA revenue forecast at $487,018,583. On average, 9 Wall Street analysts forecast VRCA's revenue for 2027 to be $697,149,493, with the lowest VRCA revenue forecast at $525,258,561, and the highest VRCA revenue forecast at $896,474,947.

In 2028, VRCA is forecast to generate $1,046,428,570 in revenue, with the lowest revenue forecast at $609,434,612 and the highest revenue forecast at $1,976,934,693.

What is VRCA's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: VRCA) forecast ROA is 114.33%, which is higher than the forecast US Biotechnology industry average of 23.46%.

What is VRCA's Price Target?

According to 1 Wall Street analyst that have issued a 1 year VRCA price target, the average VRCA price target is $12.00, with the highest VRCA stock price forecast at $12.00 and the lowest VRCA stock price forecast at $12.00.

The Wall Street analyst predicted that Verrica Pharmaceuticals's share price could reach $12.00 by May 26, 2027. The average Verrica Pharmaceuticals stock price prediction forecasts a potential upside of 154.24% from the current VRCA share price of $4.72.

What is VRCA's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: VRCA) Verrica Pharmaceuticals's current Earnings Per Share (EPS) is -$1.75. On average, analysts forecast that VRCA's EPS will be -$2.14 for 2026, with the lowest EPS forecast at -$2.31, and the highest EPS forecast at -$2.05. On average, analysts forecast that VRCA's EPS will be -$1.44 for 2027, with the lowest EPS forecast at -$1.85, and the highest EPS forecast at -$0.99. In 2028, VRCA's EPS is forecast to hit -$0.64 (min: -$1.45, max: $1.08).

What is VRCA's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: VRCA) forecast ROE is 956.06%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.